|November 26, 2013|
|11:00 EDT||SYY, NUAN, DSW, TTS, LGND||High option volume stocks: LGND DSW SYY TTS NUAN|
News For LGND;DSW;SYY;TTS;NUAN From The Last 14 Days
Check below for free stories on LGND;DSW;SYY;TTS;NUAN the last two weeks.
|March 10, 2014|
|10:13 EDT||LGND||Lundbeck announces FDA acceptance of NDA submission for Carbamazepine IV|
Captisol licensee Lundbeck LLC today announced that the U.S. Food and Drug Administration has accepted for review a New Drug Application for its investigational therapy intravenous carbamazepine, an intravenous formulation of the anti-epileptic drug carbamazepine. An action letter is anticipated before the end of 2014. Carbella Injection is the proposed U.S. trade name. With acceptance of the NDA filing, Ligand earns a $200,000 milestone payment.
|March 7, 2014|
|07:00 EDT||TTS||Piper Jaffray to hold a field trip|
Chicago Field Trip to visit with Tile Shop and Lumber Liquidators in Chicago on March 7.
|March 3, 2014|
|11:02 EDT||SYY||Sysco promotes Chief Legal Officer, Chief Accounting Officer|
Subscribe for More Information
|February 28, 2014|
|09:58 EDT||LGND||Ligand says partner GSK submits application for Promacta|
Ligand Pharmaceuticals (LGND) said its partner GlaxoSmithKline (GSK) announced today the submission of a supplemental New Drug Application to the FDA for Promacta for the treatment of cytopenias in patients with severe aplastic anaemia who have had an insufficient response to immunosuppressive therapy.
|February 24, 2014|
|09:06 EDT||LGND||Ligand price target raised to $91 from $78 at Summer Street|
Summer Street raised its price target for Ligand shares to $91 following the company's Q4 results and 2014 outlook. It keeps a Buy rating on the stock.